Short-course versus long-course neoadjuvant chemoradiotherapy in patients with rectal cancer: long-term results of a randomized controlled trial

Short-course radiotherapy (SCRT) and long-course radiotherapy (LCRT) are the primary neoadjuvant radiotherapy schedules for locally advanced rectal cancer. Recent research has questioned the efficacy of SCRT. This study presents an updated analysis of our previous research, extending the follow-up t...

Descripción completa

Detalles Bibliográficos
Autores: Aghili, Mahdi, Aghaei, Mohammad-Mahdi, Abyaneh, Romina, Babaei, Mohammad, Farhan, Farshid, Lashkari, Marzieh, Farazmand, Borna, Kolahdouzan, Kasra, Piozzi, Guglielmo Niccolò, Couñago Lorenzo, Felipe, Et.al.
Tipo de recurso: artículo
Fecha de publicación:2025
País:España
Institución:Universidad Europea (UEM)
Repositorio:ABACUS. Repositorio de Producción Científica
Idioma:inglés
OAI Identifier:oai:abacus.universidadeuropea.com:11268/16250
Acceso en línea:https://hdl.handle.net/11268/16250
Access Level:acceso abierto
Palabra clave:Neoplasias del recto
Terapia Neoadyuvante
Radioterapia
Cáncer
Tratamiento médico
Goal 3: Ensure healthy lives and promote well-being for all at all ages
Descripción
Sumario:Short-course radiotherapy (SCRT) and long-course radiotherapy (LCRT) are the primary neoadjuvant radiotherapy schedules for locally advanced rectal cancer. Recent research has questioned the efficacy of SCRT. This study presents an updated analysis of our previous research, extending the follow-up to evaluate 5-year outcomes by comparing the long-term results of these two strategies. This randomized controlled trial compared SCRT and LCRT in locally advanced middle or high rectal adenocarcinoma. The SCRT group received 25 Gy/5 fractions over 1 week plus CAPOX, while the LCRT group received 50–50.4 Gy/25–28 fractions over 5–5.5 weeks plus capecitabine. All patients received consolidation chemotherapy and then underwent delayed surgery after 8 weeks or more post-radiotherapy. The endpoints of this updated analysis include overall survival (OS),disease-free survival (DFS), locoregional recurrence (LR) and distant metastasis (DM).